| Article Access Statistics|
| Viewed||2515 |
| Printed||82 |
| Emailed||1 |
| PDF Downloaded||52 |
| Comments ||[Add] |
| Cited by others ||1 |
Click on image for details.
|Year : 2014 | Volume
| Issue : 4 | Page : 400-405
Effect of radiation dose on the outcomes of gamma knife treatment for trigeminal neuralgia: A multi-factor analysis
Xinjie Zhang, Peng Li, Shizhen Zhang, Feilong Gong, Sen Yang, Wei Wang
Department of Neurosurgery, West China Hospital of Sichuan University, Chengdu, China
|Date of Submission||13-Mar-2014|
|Date of Decision||21-Mar-2014|
|Date of Acceptance||24-Aug-2014|
|Date of Web Publication||19-Sep-2014|
Department of Neurosurgery, West China Hospital of Sichuan University, Chengdu - 610 041
Source of Support: None, Conflict of Interest: None
Aim: To analyze the effect of different radiation variables on the outcomes of treatment for trigeminal neuralgia (TN). Materials and Methods: Seventy-three patients with refractory TN were treated with a maximum dose of 75-90 Gy using either one (n = 41) or two (n = 32) isocenters and were intensively followed up. The integrated dose delivered to the trigeminal nerve root within the prepontine cistern and the nerve root volume was calculated using the Gamma-Plan system. Relationships between the clinical outcomes and radiation variables were statistically analyzed using a combination of Fisher's exact test and multivariate analyses. Results: At their last follow up, 21 patients (28.8%), 22 patients (30.1%), 19 patients (26%), 6 patients (8.2%), and 5 patients (6.8%) had Grade I-V pain outcomes, respectively, and the average mean dose delivered to the trigeminal nerve root, average integrated dose (mJ) and nerve root volume in prepontine cistern were 45.29 Gy, 4,26 mJ, and 98.47 mm 3 , respectively. The pain relief rate was not significantly improved by a higher amount of integrated dose received by the trigeminal nerve root in prepontine cistern, however, incidence of trigeminal nerve toxicity was increased (P = 0.005). Conclusions: Our limited results suggested that a higher integrated dose might increase the incidence of trigeminal nerve toxicity with no significant benefits in pain relief when the maximal doses were within 75-90 Gy. The protocol for increasing radiation variables such as longer nerve exposure length and higher maximal dose is not recommended as a routine approach and more randomized studies with large number of cases would be required to verify the best treatment strategy of gamma knife radiosurgery for TN.
Keywords: Dose-volume histogram, gamma knife, pain control rate, radiosurgery, radiation dose, trigeminal neuralgia
|How to cite this article:|
Zhang X, Li P, Zhang S, Gong F, Yang S, Wang W. Effect of radiation dose on the outcomes of gamma knife treatment for trigeminal neuralgia: A multi-factor analysis. Neurol India 2014;62:400-5
|How to cite this URL:|
Zhang X, Li P, Zhang S, Gong F, Yang S, Wang W. Effect of radiation dose on the outcomes of gamma knife treatment for trigeminal neuralgia: A multi-factor analysis. Neurol India [serial online] 2014 [cited 2020 Oct 20];62:400-5. Available from: https://www.neurologyindia.com/text.asp?2014/62/4/400/141272
FNx01Dr. Xinjie Zhang and Dr. Peng Li contributed equally to this study
| » Introduction|| |
Although gamma knife radiosurgery (GKR) represents an effective treatment option for trigeminal neuralgia, ,,, there is a lack of consensus on the best-suited treatment protocol. Radiation variables are crucial factors of the treatment protocol and can significantly affect its outcome. These variables include an ideal isocenter location, optimum irradiated nerve length, treatment volume, and maximal radiation dosage. Historically, the aim of GKR treatment for TN is to gain the best pain relief with minimal and acceptable morbidity. Though a close relationship between among the efficacy, different occurrence rate of complication, and maximal radiation dose has been reported by several studies with heterogeneous treatment philosophies, ,,,, the effect of radiation dose for the entire length of the trigeminal nerve root on pain relief and further complications is not clear. The goal of this single-institution retrospective series was to present a dose-volume data set that may help to achieve a better understanding of radiobiological effect on clinical outcomes following GKR for TN.
| » Materials and Methods|| |
Eighty patients with idiopathic TN who were medically refractory or experiencing intolerable side effects underwent GKR from July 2010 to May 2013 at our hospital. Prior to the treatment, routine magnetic resonance imaging (MRI) ruled out symptomatic TN caused by tumors, infarction, or multiple sclerosis. Seventy-three patients (90.1%) were followed up with a median time of 12 months (range: 6-37 months). The average age was 63.5 years (range: 37-87 years) and thirty patients were male. The most common area of pain was in the V1, V2, and V3 nerve distributions (31.1%). Twenty-one patients (26.3%) had undergone previous surgical procedures, including percutaneous rhizotomy (glycerol or radiofrequency ablation), GKR, and microvascular decompression. Before GKR treatment, patients had experienced the symptoms for a mean duration of 7.3 years (range: 0.25-20 years) and facial numbness had been reported by six patients. The clinical characteristics of patients are detailed in [Table 1].
A Leksell stereotactic multifunctional frame (Elekta Instruments, Sweden) was attached to the patients' head, parallel to the trigeminal nerve root, under local infiltration anesthesia in a standard manner. Using the sequences of turbo spin echo and constructive interference in steady state sequences, MRI images were fused for preoperational location by the image fusion function of GammaPlan version 9.0 (Elekta Instruments). The maximum central doses of 75-90 Gy were delivered to the patients with single isocenter (56.2%) or double isocenters (43.8%) in 4 mm. The target of the treatment was the trigeminal nerve root entry zone (REZ). All patients underwent treatments using Leksell Gamma Knife model C (Elekta Instruments, Stockholm, Sweden). Plug pattern was used to limit the doses to the pons if necessary [Figure 1].
|Figure 1: (a and b) MRI presentation. axial MRI showing green isodose line of 20 Gy, yellow isodose line of 42.5 Gy, use two 4-mm shots|
Click here to view
Outcome assessment and analysis
Regular follow-up visits were suggested at 3, 6, 12 months, and annually thereafter following GKR. Telephonic or personal interview were used to obtain follow-up information, including the time to the onset of pain relief, the degree of pain relief, and treatment complications by two medical residents who were "blind" to the patients' medical history. Based on the Barrow Neurological Institute (BNI) score for TN,  we classified pain relief after treatment into five grades: Grade I = no pain without medication, Grade II = occasional pain not requiring medication, Grade III = some pain adequately controlled by medication, Grade IV = some pain not adequately controlled by medication, and Grade V = severe pain with no pain relief. We defined Grade IV and Grade V as treatment failure. Using the dose-volume histogram module of GammaPlan, we retrospectively calculated the mean and integrated dose delivered to the trigeminal nerve root within the prepontine cistern and the nerve root volume, respectively [Figure 2]. The relationships between pain relief outcome, trigeminal nerve dysfunction, different dosimetric variables, age of patients, and previous neurosurgical procedure for TN were further analyzed.
|Figure 2: MRI presentation. examples of the using of isodoses and irradiation of the volume of the trigeminal nerve, red outline volumetric contour of the nerve root in prepontine cistern|
Click here to view
Statistical analysis was performed with the Statistical Package for the Social Sciences software (version 14.0; SPSS, Chicago, IL, USA). Fisher's exact test was used for nominal data. Multivariate analysis was performed to determine the significance of radiation variables factors to pain relief and complication by using stepwise logistic regression. Statistical significance was set at a P value of ≤ 0.05.
| » Results|| |
Depending on the GammaPlan treatment planning system, we calculated several dosimetric variables, which are summarized in [Table 2]. The average mean dose delivered to the trigeminal nerve root, average integrated dose (mJ) and nerve root volume in prepontine cistern were 45.29 Gy, 4.26 mJ, and 98.47 mm 3 , respectively. By using multiple linear regression, we found that the mean dose (P < 0.001), nerve root volume in prepontine cistern (P < 0.001), and number of shots (P < 0.001) were significantly related to the integrated dose (mJ).
|Table 2: Follow-up data for different dosimetric variables, nerve dysfunction and pain control|
Click here to view
At their last follow-ups, 21 patients (28.8%), 22 patients (30.1%), 19 patients (26%), 6 patients (8.2%), and 5 patients (6.8%) had GRADE I-V pain outcomes respectively. Sixty-two out of 73 patients (84.9%) reported an improvement in pain after GKR. We did not observe a significant relationship between integrated dosage (mJ) and pain relief using logistic regression. The results of multiple logistic regression revealed that the center dose, number of isocenters, nerve root volume in prepontine cistern, age of patients, sex, and previous neurosurgical procedure for TN did not affect treatment efficacy significantly as summarized in [Table 3]. However, the development of post-treatment trigeminal nerve dysfunction and pain side was significant impact factors for improving treatment efficacy. The median time to onset of pain relief was 1 month after radiosurgery (range: immediately to 18 months). The difference in latency was not significantly related to the prescribed and integrated doses delivered to the volume of the trigeminal nerve root within the prepontine cistern. Recurrence was observed in 9 of 62 (14.52%) responding patients at a median time of 18 months (range: 2-42 months) after pain relief. Of these 9 patients, 3 had Grade I relief and 6 had Grade III relief initially.
|Table 3: Analysis of variables potentially affecting the chances after radiosurgery|
Click here to view
Newly developed or increased trigeminal nerve dysfunction (numbness or paresthesia) were observed in 29 patients (39.7%), none of which experienced dysgeusia, dry eye syndrome, or anesthesia dolorosa after GKR. The trigeminal dysfunction was persistent during follow up and within patients that reported trigeminal nerve dysfunction; 11/29 (37.91%), 12/29 (41.38%), 5/29 (17.27%), and 1/29 (3.45%) achieved Grade I, II, III, and IV pain relief, respectively, with none of the patients experiencing Grade V pain relief. We observed a significant trend for increased incidence of trigeminal dysfunction when higher integrated doses were administered to the trigeminal nerve root within the prepontine cistern by univariate analyses (P = 0.005), despite the small number of cases. A significant difference was also found in trigeminal nerve toxicity incidence between two-isocenters and one-isocenter (P = 0.003).
| » Discussion|| |
The results of this study suggested that the pain relief rate was not significantly improved by a higher amount of integrated dose received by the trigeminal nerve root in prepontine cistern; on the contrary, increasing the incidence of trigeminal nerve toxicity. Integrated dose is influenced by many factors, such as the mean dose, maximal dose, trigeminal nerve root volume in the prepontine cistern, and number of shots or nerve length irradiated in this study.
Kondziolka et al.  found that greater than 70 Gy should be prescribed for trigeminal neuralgia radiosurgery. Subsequently, Regis et al.  alleged that maximal dose of more than 90 Gy would increase the incidence of facial sensory loss and paresthesia. Therefore, it is generally accepted that the maximal radiation doses in treatment of TN should be prescribed between 70 and 90 Gy. As a traditional method, studies of GKR for TN are usually described by the maximal dose, which may be the most important factor of the treatment protocol. However, the results of our study and that of aforementioned studies ,, suggest that the pain relief rate and trigeminal nerve dysfunction were related not only to the maximal dose but also to many other factors, for example, cumulative dose. Dvorak et al.  reported that cumulative dose more than 130 Gy was more likely to result in successful pain control, but was also more likely to develop new neural dysfunction. While Huang et al.  indicated that cumulative doses above 115 Gy were found to be associated with non-facial numbness and facial numbness. Radiosurgery as a destructive technique itself correlates pain relief outcome after radiosurgery and trigeminal nerve injury together. Although the patients treated with higher dose might experience a higher rate of pain relief after GKR treatment  (but this increase is not in accordance with increased incidences of complications), simply increasing the prescript dose without limit might also increase the incidence and severity of postoperative complications beyond a patient's tolerance capacity. ,, Though we and others did not observe a statistical significance when considering the role of an integrated dose or maximal doses for evaluating the pain relief rate within a therapeutic window of 75-97 Gy for TN albeit with higher complication rates, ,,, we may use a relatively lower prescribed dose, higher than 70 Gy,  to prevent increased toxicity rates. In addition, we supposed that an integrated dose to the trigeminal nerve root might provide useful information to understand better the radiobiological effects on clinical outcomes following GKR for TN.
Our study as well as other studies use the root entry zone within the trigeminal nerve as the most suitable target, since this region is the transition point from Schwann cells to oligodendrocytes and may provide a difference in radiosensitivity along the nerve.  Alternatively, Régis et al. pointed out that a high-dose irradiation of the proximal nerve root could potentially endanger it and suggested an anterior targeting method as an alternative to avoid complications with superior pain control.  While compared to REZ, the distal targeting method studies did not significantly reduce the rate of complications. ,, These series imply the lesion of the trigeminal nerve in prepontine cistern is more important than proximal/distal isocenter location while considering complication rates.
Radiation exposure length of the trigeminal nerve (number of shots) was directly related to the radiosurgery treatment volume and integrated dose for the trigeminal nerve root. Our results (higher rate of trigeminal dysfunction without significantly increased pain relief rate) were similar to some of previous studies that increased irradiation length of the nerve. ,,, Analogously, based on the results of Marshall K's study,  patients with shorter length of trigeminal nerve in prepontine cistern could have better outcomes during follow up. Interestingly, one study reported that greater brainstem exposure volumes and lower trigeminal nerve treatment volume might result in improved pain relief without a significant difference in trigeminal nerve toxicity.  This study implies that the distance between isocenter and the brainstem may affect treatment outcome. Conversely, in our study, the trigeminal nerve treatment volume irradiated in the prepontine cistern did not directly influence the pain outcome and complication. To the best of our knowledge, there is an inverse relationship between brainstem exposure volumes and trigeminal nerve treatment volume. This is because the increasing diameter and length of the nerve lend credence to farther and larger anatomical targets and a higher prescription dose along the nerve (concerned that radiation dose received by the brainstem being too high to tolerate). Therefore, the trigeminal nerve volume in the prepontine cistern, though not equal to treatment volume, has an individualized anatomical factor and may indirectly influence the outcome of treatment.
In the present study, initial treatment history was not a factor that affected pain control or complication, consistent with previously published reports, ,, while contradicting other analyses. ,,, This may be caused by the heterogeneous duration of symptoms, side and distribution of pain, treatment factors, presence of preoperative facial anesthesia, and treatment philosophies. Secondly, we may make prior invasive treatment a gross over simplification. Little, A. S et al. suggested that unlike other invasive procedures, the strongest predictor of GKRS failure was a history of prior MVD.  This implies prior invasive treatments may be more different from each other than we think and these treatments cannot be analyzed as a single factor. In addition, the type of pain that patients suffered from in our study was not identical. Atypical features or typical pain type may influence our data analyses differently. Of note, this is not the end-point of observation for most of the patients and a longer follow-up period is necessary to fully assess the incidence of late complication and recurrence.  Hence, the results of patients in the present series are self-limiting and a continuous follow-up is yet to be carried out. Our results suggest that there may be a threshold of an integrated dose in the treatment of TN with GKR, which can provide promising treatment effects and acceptable complications, provided we increased the number of cases included in this study to enable us to accomplish a complicated and meticulous difference significantly.
| » References|| |
|1.||Rogers CL, Shetter AG, Fiedler JA, Smith KA, Han PP, Speiser BL. Gamma knife radiosurgery for trigeminal neuralgia: The initial experience of The Barrow Neurological Institute. Int J Radiat Oncol Biol Phys 2000;47:1013-9. |
|2.||Flickinger JC, Pollock BE, Kondziolka D, Phuong LK, Foote RL, Stafford SL, et al. Does increased nerve length within the treatment volume improve trigeminal neuralgia radiosurgery? A prospective double-blind, randomized study. Int J Radiat Oncol Biol Phys 2001;51:449-54. |
|3.||Morbidini-Gaffney S, Chung CT, Alpert TE, Newman N, Hahn SS, Shah H, et al. Doses greater than 85 Gy and two isocenters in Gamma Knife surgery for trigeminal neuralgia: Updated results. J Neurosurg 2006;105 Suppl: 107-11. |
|4.||Massager N, Murata N, Tamura M, Devriendt D, Levivier M, Régis J. Influence of nerve radiation dose in the incidence of trigeminal dysfunction after trigeminal neuralgia radiosurgery. Neurosurgery 2007;60:681-7. |
|5.||Li P, Wang W, Liu Y, Zhong Q, Mao B. Clinical outcomes of 114 patients who underwent gamma-knife radiosurgery for medically refractory idiopathic trigeminal neuralgia. J Clin Neurosci 2012;19:71-4. |
|6.||Kim YH, Kim DG, Kim JW, Kim YH, Han JH, Chung HT, et al. Is it effective to raise the irradiation dose from 80 to 85 Gy in gamma knife radiosurgery for trigeminal neuralgia? Stereotact Funct Neurosurg 2010;88:169-76. |
|7.||Park SH, Hwang SK, Kang DH, Park J, Hwang JH, Sung JK. The retrogasserian zone versus dorsal root entry zone: Comparison of two targeting techniques of gamma knife radiosurgery for trigeminal neuralgia. Acta Neurochir (Wein) 2010;152:1165-70. |
|8.||Marshall K, Chan MD, McCoy TP, Aubuchon AC, Bourland JD, McMullen KP, et al. Predictive variables for the successful treatment of trigeminal neuralgia with gamma knife radiosurgery. Neurosurgery 2012;70:566-72. |
|9.||Kondziolka D, Lunsford LD, Flickinger JC, Young RF, Vermeulen S, Duma CM, et al. Stereotactic radiosurgery for trigeminal neuralgia: A multiinstitutional study using the gamma unit. J Neurosurg 1996;84:940-5. |
|10.||Regis J, Bartolomei F, Metellus P, Rey M, Genton P, Dravet C, et al. Radiosurgery for trigeminal neuralgia and epilepsy. Neurosurg Clin N Am 1999;10:359-77. |
|11.||Matsuda S, Nagano O, Serizawa T, Higuchi Y, Ono J. Trigeminal nerve dysfunction after Gamma Knife surgery for trigeminal neuralgia: A detailed analysis. J Neurosurg 2010;113 Suppl: 184-90. |
|12.||Dvorak T, Finn A, Price LL, Mignano JE, Fitzek MM, Wu JK, et al. Retreatment of trigeminal neuralgia with Gamma Knife radiosurgery: Is there an appropriate cumulative dose? Clinical article. J Neurosurg 2009;111:359-64. |
|13.||Huang CF, Chuang JC, Tu HT, Lin LY. Repeated Gamma Knife surgery for refractory trigeminal neuralgia. J Neurosurg 2006;105 Suppl: 99-102. |
|14.||Pollock BE, Phuong LK, Foote RL, Stafford SL, Gorman DA. High-dose trigeminal neuralgia radiosurgery associated with increased risk of trigeminal nerve dysfunction. Neurosurgery 2001;49:58-62. |
|15.||Longhi M, Rizzo P, Nicolato A, Foroni R, Reggio M, Gerosa M. Gamma knife radiosurgery for trigeminal neuralgia: Results and potentially predictive parameters-part I: Idiopathic trigeminal neuralgia. Neurosurgery 2007;61:1254-60. |
|16.||Regis J. High-dose trigeminal neuralgia radiosurgery associated with increased risk of trigeminal nerve dysfunction. Neurosurgery 2002;50:1401-2. |
|17.||Riesenburger RI, Hwang SW, Schirmer CM, Zerris V, Wu JK, Mahn K, et al. Outcomes following single-treatment Gamma Knife surgery for trigeminal neuralgia with a minimum 3-year follow-up. J Neurosurg 2010;112:766-71. |
|18.||Yamamoto M. Japanese Experience with Gamma Knife Radiosurgery. Vol. 22. Berlin, Germany: Karger Medical and Scientific Publishers; 2009. |
|19.||Massager N, Nissim O, Murata N, Devriendt D, Desmedt F, Vanderlinden B, et al. Effect of beam channel plugging on the outcome of gamma knife radiosurgery for trigeminal neuralgia. Int J Radiat Oncol Biol Phys 2006;65:1200-5. |
|20.||Kanner AA, Neyman G, Suh JH, Weinhous MS, Lee SY, Barnett GH. Gamma knife radiosurgery for trigeminal neuralgia: Comparing the use of a 4-mm versus concentric 4- and 8-mm collimators. Stereotact Funct Neurosurg 2004;82:49-57. |
|21.||Brisman R, Mooij R. Gamma knife radiosurgery for trigeminal neuralgia: Dose-volume histograms of the brainstem and trigeminal nerve. J Neurosurg 2000;93 Suppl 3:155-8. |
|22.||Huang CF, Chiou SY, Wu MF, Tu HT, Liu WS. Gamma Knife surgery for recurrent or residual trigeminal neuralgia after a failed initial procedure. J Neurosurg 2010;113 Suppl: 172-7. |
|23.||Park KJ, Kondziolka D, Berkowitz O, Kano H, Novotny J Jr, Niranjan A, et al. Repeat gamma knife radiosurgery for trigeminal neuralgia. Neurosurgery 2012;70:295-305. |
|24.||Kondziolka D, Lunsford LD, Flickinger JC. Stereotactic radiosurgery for the treatment of trigeminal neuralgia. Clin J Pain 2002;18:42-7. |
|25.||Dhople AA, Adams JR, Maggio WW, Naqvi SA, Regine WF, Kwok Y. Long-term outcomes of Gamma Knife radiosurgery for classic trigeminal neuralgia: Implications of treatment and critical review of the literature. Clinical article. J Neurosurg 2009;111:351-8. |
|26.||Dellaretti M, Reyns N, Touzet G, Sarrazin T, Dubois F, Lartigau E, et al. Clinical outcomes after Gamma Knife surgery for idiopathic trigeminal neuralgia: Review of 76 consecutive cases. J Neurosurg 2008;109 Suppl: 173-8. |
|27.||Little AS, Shetter AG, Shetter ME, Kakarla UK, Rogers CL. Salvage gamma knife stereotactic radiosurgery for surgically refractory trigeminal neuralgia. Int J Radiat Oncol Biol Phys 2009;74:522-7. |
|28.||McNatt SA, Yu C, Giannotta SL, Zee CS, Apuzzo ML, Petrovich Z. Gamma knife radiosurgery for trigeminal neuralgia. Neurosurgery 2005;56:1295-301. |
[Figure 1], [Figure 2]
[Table 1], [Table 2], [Table 3]
|This article has been cited by|
||Schwannomas from Olfactory Nerve: A Rare Type
| ||Mohamed Amin Ghobadifar |
| ||Indian Journal of Surgical Oncology. 2015; |
|[Pubmed] | [DOI]|